PT and PTT Illustrated Mechanisms

For an illustrated overview of the hemostasis mechanisms associated with the PT and PTT, obtain this article from your medical library: Harris NS, Marin MJ, Butenas S. Beyond prothrombin time and activated partial thromboplastin time: coagulation in vivo-an illustrated review. Lab Med. 2025;56:438–47. doi: 10.1093/labmed/lmae125. PMID: 40319459. Abstract The steps that initiate coagulation in vivo […]

Comments (0)

Coagulation Factors

Oct 29 2025

george

Protein C Concentrate Therapy

To see the open-access results of a primary study about therapeutic PC, click Manco-Johnson M, Brons P, Knoebl P, et al. Real-world use of protein C concentrate for the treatment of patients with protein C deficiency: an international registry. J Thromb Haemost. 2025;23:3569–77. doi: 10.1016/j.jtha.2025.07.018. PMID: 40706962. Abstract Background Published reports on the real-world use […]

Blog

Gene Transfer Therapy Updates

Yesterday, 10-28-25, we reported BioMarin’s press release announcing divestiture of their hemophilia A gene transfer therapy, valoctocogene roxaparvovec (Roctavian®). Previously, on February 25, 2025, Pfizer announced their intention to discontinue hemophilia B gene transfer therapy, fidanacogene elaparvovec-dzkt (Becvez®). Press releases from both indicate underperformance in sales. The remaining hemophilia B therapy, etranacogene dezaparvovec-drlb (HEMGENIX®), CSL […]

Bleeding Disorders

November 2025 QQ: Stuart-Prower Factor

Our November 2025 Quick Question tests our historical knowledge. Not long ago, we learned about various names for the coagulation factors; e. g., proaccelerin, proconvertin, and plasma thromboplastin antecedent. Some factor names were proper nouns, for example, Hageman factor, Fletcher factor, and Fitzgerald factor. This month’s question asks you to identify the Stuart-Prower factor by […]

Comments (0)

Quick Question Archive

Oct 28 2025

george

BioMarin Plans to Divest Struggling Gene Therapy

Thanks to Dean Willett of Precision BioLogic Inc. for the heads-up on BioMarin’s 10-27-25 post announcing their divestment of the hemophilia A gene transfer therapy, Roctavian. See BioMarin’s 10-27 press release.

Bleeding Disorders

October 2025 QQ: Reporting Assay Uncertainty Data Summary

Our October 2025 Quick Question was a poll that asked, “Do you support publishing assay uncertainty data with all results?” The poll attracted 13 respondents who answered: Yes: 4 (31%) No: 8 (62%) It depends: 1 (7%) While the response was small, our question attracted several vigorous comments (click). Generalizing, this hourglass figure, cited in Stroobants […]

Comments (0)

Quick Question Archive

Oct 27 2025

george

A Coag Conversation: Alternate Warfarin Monitoring When the Prothrombin Time is Unreliable – Part 1

Join me (Geo) and guest speaker Dr. Nicole Zantek, MD, PhD, Medical Director of the Special Coagulation Laboratory, Professor, Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, who discusses the pathophysiology of antiphospholipid antibodies, and alternative methods to monitor warfarin and DOAC anticoagulation in patients diagnosed with antiphospholipid syndrome. This is the […]

Comments (0)

Anticoagulant Therapy

Oct 25 2025

george

International Symposium on Intensive Care and Emergency Medicine: Nebulizer Delivery of Unfractionated Heparin

Thanks to Dave McGlasson, MS, MLS, for the heads-up about this open-access review of the International Symposium on Intensive Care and Emergency Medicine (Click Here). Bateman RM, Sharpe MD, Jagger JE, et al. 36th International Symposium on Intensive Care and Emergency Medicine: Brussels, Belgium. 15–18 March 2016. Crit Care. 20160;20(Suppl 2):94. doi: 10.1186/s13054-016-1208-6. Erratum in: […]

Comments (0)

Anticoagulant Therapy

Oct 25 2025

george

The Blood Project: TTP Module

Click here for a comprehensive review of TTP. This is a segment within The Blood Project, a not-for-profit organization committed to advancing medical knowledge about the crucial role of blood in human health, disease, and therapeutics. TBP offers open-access, web-based, and expertly curated learning tools and resources with the following goals: Enhance Hematological Knowledge: TBP […]

Bleeding Disorders

Precision BioLogic Webinar: Advancing Hemophilia A Testing with a Bovine Chromogenic FVIII Assay

Listen as Precision BioLogic’s Chief Scientific Officer F. Jon Geske, PhD and Marketing Director Ian Burns chair the webinar, Advancing Hemophilia A Testing with a Bovine Chromogenic FVIII Assay. Joining them are… Tara Quinton, R&D Scientist and part of Precision BioLogic’s Chromogenic FVIII assay design team, discussing the assay’s expanded utility along with new data […]

Comments (0)

Bleeding Disorders

All Posts

PT and PTT Illustrated Mechanisms

Protein C Concentrate Therapy

Gene Transfer Therapy Updates

November 2025 QQ: Stuart-Prower Factor

BioMarin Plans to Divest Struggling Gene Therapy

October 2025 QQ: Reporting Assay Uncertainty Data Summary

A Coag Conversation: Alternate Warfarin Monitoring When the Prothrombin Time is Unreliable – Part 1

International Symposium on Intensive Care and Emergency Medicine: Nebulizer Delivery of Unfractionated Heparin

The Blood Project: TTP Module

Precision BioLogic Webinar: Advancing Hemophilia A Testing with a Bovine Chromogenic FVIII Assay

George Fritsma MS MLS

Cheat Sheets from George

Questions or Comments?

Quick Question